
SELLAS Life Sciences announced positive Phase 3 REGAL trial results for their cancer vaccine Galinpepimut-S (GPS) in acute myeloid leukemia (AML) patients. GPS reduced the risk of death by 41%, extending median overall survival to 24 months compared to 14.7 months with best available treatments. The vaccine was well tolerated with mostly mild side effects. SELLAS plans to meet the FDA soon to discuss accelerated approval and aims to submit a Biologics License Application in early 2027, potentially offering a new treatment option for AML patients in second remission who cannot undergo stem cell transplants.
SELLAS Life Sciences (SLS) shares rose 7.10% to USD 8.00 as of Nov 17, 2026 19:12 WIB on Pluang, trading closer to the middle of its 52-week range between USD 1.39 and USD 15.46. Despite the positive Phase 3 trial news, the stock remains well below its 52-week high, reflecting ongoing market caution. Buy orders dominate at 96%, indicating strong investor interest in the health sector name.